Development & Strategy
Joe Skelton brings more than a decade of experience across business development, corporate development, and life sciences investment banking, with completed transaction experience exceeding $9 billion across M&A, licensing, and capital markets. Prior to joining Cosette, he served as Chief Financial Officer of I-Mab Biopharma (now NovaBridge), where he led capital markets strategy, business development initiatives, and operational transformation across the U.S. and Asia. During his tenure, he delivered significant shareholder value through capital optimization, strategic divestitures, and disciplined portfolio management.
Prior to I-Mab, Joe was a Senior Vice President in Life Sciences Investment Banking at Truist Securities, where he advised biotechnology, specialty pharma, and generics companies on M&A and capital formation transactions. Earlier in his career, he held roles at Amneal Pharmaceuticals, where he supported corporate development and inorganic growth initiatives, as well as at Cantor Fitzgerald, Janney Montgomery Scott, and Ernst & Young.
My role at Cosette is part science, part strategy, and part deal-making—connecting medicines with the resources they need to reach patients. I’m driven by the challenge of finding smart, creative ways to build value while keeping patient impact at the center of every decision—and getting comfortable making calculated leaps when the data (mostly) agrees.
